• OPEN AN ACCOUNT
Indian Indices
Sensex
82,814.71 316.57
( 0.38%)
Global Indices
Nasdaq
49,410.74 -272.93
(-0.55%)
Dow Jones
6,881.90 -20.41
(-0.30%)
Hang Seng
56,838.27 -629.56
(-1.10%)
Nikkei 225
10,620.33 -65.85
(-0.62%)
Forex
USD-INR
90.70 0.01
(0.01%)
EUR-INR
107.23 -0.14
(-0.13%)
GBP-INR
122.83 -0.27
(-0.22%)
JPY-INR
0.59 0.00
(-0.51%)

EQUITY - MARKET SCREENER

RBM Infracon Ltd
Industry :  Construction
BSE Code
ISIN Demat
Book Value()
77929
INE0NA301016
120.3404929
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
RBMINFRA
12.12
357.14
EPS(TTM)
Face Value()
Div & Yield %
29.17
10
0
 

Pfizer gains after Q2 PAT rises 19% YoY
Nov 13,2025
On a standalone basis, net sales stood at Rs 642.34 crore, rising 9.1% year-on-year from Rs 588.59 crore in Q2 FY25 and 6.5% sequentially from Rs 603.05 crore in Q1 FY26.

Net profit (PAT) rose 19.4% YoY to Rs 189.02 crore, compared with Rs 158.35 crore in Q2 FY25, as current tax expense increased 9.4% to Rs 65.49 crore. Sequentially, PAT was down 1.4% from Rs 191.75 crore in Q1 FY26.

Profit before tax (PBT) climbed 18.7% YoY to Rs 255.37 crore, though slightly lower by 1.6% QoQ.

Total expenditure inched up 3.3% YoY and 4.9% QoQ to Rs 412.41 crore. Raw material costs declined 8.7% YoY to Rs 70 crore, while employee expenses fell 6% YoY to Rs 94.67 crore. Depreciation stood at Rs 14.28 crore, down 4.74% year-on-year, while interest expenses were steady at Rs 2.13 crore.

Net cash flow from operating activities stood at Rs 599.47 crore in H1 FY26, as against a cash flow of Rs 349.43 crore in H1 FY25.

Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.